Critical Care
Volume 9
Issue 4 |
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
This article is part of a series on Ethics, edited by Dr Laura Hawryluck.CommentaryThe benefits and threats of research partnerships with industryGordon DuVal  University of Toronto Joint Centre for Bioethics, Toronto, Canada  author email corresponding author email
Critical Care 2005,
9:309-310doi:10.1186/cc3539 First paragraph (this article has no abstract)
During the past two decades, the involvement of non-academic sponsors of biomedical research, particularly clinical trial research, has increased exponentially. It is estimated that between 1980 and 2003 the overall research and development expenditure by US pharmaceutical companies increased from $2 billion to $33 billion [1]. The sources of funding for biomedical research have also shifted significantly towards industry. By 2002, 70% of funding for clinical trials came from industry [2]. The involvement of industry partners in research has undoubted benefits. Drug development is extraordinarily expensive, and government and other non-commercial sources of research funding have generally not been able to or willing to underwrite the enormous sums necessary to develop and test the medications and devices that have made remarkable improvements in the lives of so many. | 
on Google Scholar
